Article Information
History
- February 8, 2024.
Article Versions
- Version 1 (April 1, 2022 - 16:06).
- You are currently viewing Version 2 of this article (February 8, 2024 - 12:37).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Daniel Osorio1,*,✉,
- Parastoo Shahrouzi2,*,
- Xavier Tekpli2,
- Vessela N. Kristensen2,3 and
- Marieke L. Kuijjer1,4,5,✉
- 1Centre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo, Norway
- 2Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway
- 3Department of Clinical Molecular Biology and Laboratory Science (EpiGen), Division of Medicine, Akershus University Hospital, Lørenskog, Norway
- 4Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
- 5Leiden Center for Computational Oncology, Leiden University Medical Center (LUMC), Leiden, The Netherlands
- ↵✉Correspondence: daniecos{at}uio.no & marieke.kuijjer{at}ncmm.uio.no
↵* These authors contributed equally to this work
Posted February 08, 2024.
Drug combination prediction for cancer treatment using disease-specific drug response profiles and single-cell transcriptional signatures
